Therapy Areas: Respiratory
Akeso publishes ivonescimab Phase II study results in Nature Medicine
6 November 2026 - Chinese pharmaceutical company Akeso Inc (HKEX:9926) announced on Thursday that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivo...
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
4 November 2026 - Swedish precision oncology company CHOSA Oncology AB (Spotlight Stock Market: CHOSA) said on Wednesday it has signed an agreement with a CLIA-certified laboratory to develop and vali...
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
4 November 2026 - Biotechnology company United Therapeutics Corporation (Nasdaq:UTHR) announced on Wednesday that it has entered into an amended agreement with Arena Pharmaceuticals, a subsidiary of P...
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
3 November 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has initiated ENHANCE-3, a Phase 3 clinical trial evalua...
Roche wins FDA clearance for customisable respiratory pathogen test
2 November 2026 - Healthcare company Roche (SIX: RO, ROP) (OTCQX: RHHBY) announced on Monday that it has received US Food and Drug Administration 510(k) clearance for its cobas eplex respiratory patho...
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
2 November 2026 - INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercialising DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectiou...